Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious

BenzingaNov 2 02:25

Bristol-Myers Squibb Analyst Ratings

BenzingaNov 1 23:34 · Ratings

Bristol Myers Posts Long-term Phase 3 Data for Schizophrenia Drug Cobenfy

Seeking AlphaNov 1 22:46

Entergy Analyst Ratings

BenzingaNov 1 21:07 · Ratings

Top 2 Utilities Stocks That May Crash This Quarter

BenzingaNov 1 19:34

Bristol Myers Squibb Announced Topline Data From Its Phase 3 Study Of COBENFY That Showed Continuing Improvement In Symptoms Of Schizophrenia

BenzingaNov 1 04:19